e-Drug3D

1626

SOFOSBUVIR

INN
SOFOSBUVIR

cas 1190307-88-0

CLASS

ANTIINFECTIVES
TREATMENT OF CHRONIC HEPATITIS C (CHC) INFECTION
HEPATITIS C VIRUS (HCV) NUCLEOTIDE ANALOG NS5B POLYMERASE INHIBITOR

ROUTE (list)

ORAL

ATC code

J05AP08
J05AP51
J05AP55
J05AP56

PK parameters

Tmax 1.25 HOUR
PPB 63 PERCENT
t1/2 0.4 HOUR

Solubility

SLIGHTLY SOLUBLE IN WATER

Target

TARGET HEPATITIS C VIRUS (HCV) NUCLEOTIDE ANALOG NS5B POLYMERASE

PDB
8FHS (HUMAN L-TYPE VOLTAGE-GATED CALCIUM CHANNEL CAV1.2 IN THE PRESENCE OF AMIODARONE AND SOFOSBUVIR AT 3.3 ANGSTROM RESOLUTION)

Ligand code = WG6 (link to the list of PDB complexes)

Download experimental 3D coordinates of WG6 with added hydrogens

DrugCentral

NS5B protein UNIPROT Q8JXU8 NS5B

Genome polyprotein UNIPROT P27958

Download SDF file

(S)-Isopropyl 2-((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2yl)methoxy)-(phenoxy)phosphorylamino)propanoate

Formula:
C22H29FN3O9P

Calculated chemical properties:

MW 529.45
NB_atoms 36
XLogP 1.66
PSA 153.138
NB_HD 3
NB_HA 12
fsp3 0.50
Lipinski(0=no;1=yes) 0

FDA
NDA 204671 (label) INN (SOFOSBUVIR) SOVALDI (GILEAD SCIENCES INC) APPROVAL= AP YEAR= 2013 NEWMOLECULARENTITY
NDA 205834 (label) INN (LEDIPASVIR ; SOFOSBUVIR) HARVONI (GILEAD SCIENCES INC) APPROVAL= AP YEAR= 2014
NDA 208341 (label) INN (SOFOSBUVIR ; VELPATASVIR) EPCLUSA (GILEAD SCIENCES INC) APPROVAL= AP YEAR= 2016
NDA 209195 (label) INN (SOFOSBUVIR ; VELPATASVIR ; VOXILAPREVIR) VOSEVI (GILEAD SCIENCES INC) APPROVAL= AP YEAR= 2017
NDA 212477 (label) INN (LEDIPASVIR ; SOFOSBUVIR) HARVONI (GILEAD SCIENCES INC) APPROVAL= AP YEAR= 2019
NDA 212480 (label) INN (SOFOSBUVIR) SOVALDI (GILEAD SCIENCES INC) APPROVAL= AP YEAR= 2019
NDA 214187 (label) INN (SOFOSBUVIR ; VELPATASVIR) EPCLUSA (GILEAD SCIENCES INC) APPROVAL= AP YEAR= 2021
NDA 211353 (pdf not found) INN (SOFOSBUVIR) SOFOSBUVIR (TEVA PHARMS USA INC) APPROVAL= AP YEAR= 2022 DISCONTINUED